A healthcare provider named in a qui tam complaint under the False Claims Act often learns that by the time the seal lifts, the relator's lawyers, not the Department of Justice, are the ones still driving the case. The first real test of that complaint is a motion to dismiss under Federal Rule of Civil Procedure 9(b), which requires fraud allegations to be pleaded with particularity, a higher bar than ordinary notice pleading. For a hospital, pharmacy, or physician group facing a complaint built from billing patterns and inference, whether it survives Rule 9(b) can decide the matter before discovery opens.
What Rule 9(b) Demands of a Qui Tam Complaint
Rule 9(b) requires a party alleging fraud to state the circumstances constituting the fraud with particularity, while intent and other conditions of mind may be alleged generally. Courts applying the rule to a False Claims Act complaint look for the who, what, when, where, and how of the alleged false claims, not a generic description of the scheme. The baseline plausibility standard from Bell Atlantic Corp. v. Twombly and Ashcroft v. Iqbal still applies, but Rule 9(b) adds a fraud-specific requirement: enough detail to answer the complaint, not merely enough to guess at it. A complaint alleging a compliance failure in general terms, without identifying the claims for payment that resulted, is what courts dismiss most often.
The Circuit Split Over Representative Claims
Federal appeals courts disagree on how much detail that requires. The Fourth, Sixth, Eighth, and Eleventh Circuits generally require a relator to identify at least one representative claim, an actual bill submitted for payment, with its time and amount. The Fourth Circuit's United States ex rel. Nathan v. Takeda Pharmaceuticals North America, Inc., 707 F.3d 451 (4th Cir. 2013), sets out the Fourth Circuit's version of that approach.
The First, Third, Fifth, Seventh, and Ninth Circuits take a more flexible view: a relator may instead plead particular details of the scheme paired with reliable indicia that claims were actually submitted, without pinpointing a specific invoice. United States ex rel. Grubbs v. Kanneganti, 565 F.3d 180 (5th Cir. 2009), set the Fifth Circuit's standard, later adopted by the Third Circuit in Foglia v. Renal Ventures Management, LLC, 754 F.3d 153 (3d Cir. 2014). The Supreme Court has repeatedly declined to resolve the split, most recently denying certiorari on October 17, 2022 in United States ex rel. Owsley v. Fazzi Associates, Inc.
Partial Dismissal and the Limits of Leave to Amend
A Rule 9(b) motion rarely produces an all-or-nothing result. A healthcare qui tam complaint often pleads several theories at once, upcoding, medically unnecessary services, a kickback tie-in, and a court can dismiss the theories lacking required detail while letting a better-pleaded theory proceed. Courts usually grant leave to amend a dismissed theory under Rule 15(a)'s liberal standard from Foman v. Davis, 371 U.S. 178 (1962), unless amendment would be futile. Dismissal with leave to amend narrows the case rather than ending it: it forces the relator to commit to specific claims and dates, and tests early whether the promised indicia actually exist.
A motion that narrows a qui tam complaint to its provable theories can do as much for a provider's defense as an outright dismissal.
The First Contested Step After the Seal Lifts
Once the seal lifts and the government has decided whether to intervene, the relator's counsel must defend the complaint's sufficiency before merits discovery opens, which is why a Rule 9(b) motion is usually the first contested step in the case. It gives the defense an early, document-light chance to test the complaint on its face. Executives named individually alongside the corporate defendant face the same scrutiny, an exposure covered in Individual Liability for Executives Under the FCA. Complaints built on an implied certification theory, the subject of Implied Certification After Escobar, carry particularity problems layered on top of the Rule 9(b) standard. A separate motion may raise the first-to-file rule or the public disclosure bar, each of which can end a qui tam case outright on its own terms. A complaint that survives Rule 9(b) moves toward discovery, where a settlement or loss can also bring a corporate integrity agreement.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers promptly retain experienced healthcare defense counsel upon receiving a qui tam complaint, a civil investigative demand, or notice that a seal has lifted. Early legal intervention can protect the provider's rights, shape the Rule 9(b) motion before the relator amends around the complaint's weaknesses, avoid inadvertent admissions in preliminary correspondence, and allow counsel to communicate with the government and relator's counsel on the provider's behalf. Delaying representation narrows the window to test a poorly pleaded complaint, and the provider's own insurer often disputes those defense costs separately, covered in Insurance Coverage for FCA Defense Costs.
How Health Law Alliance Can Help
Health Law Alliance has handled 5,000+ matters across healthcare regulatory and fraud defense over 25+ years, including qui tam complaints at the motion to dismiss stage. If your organization has been named in a False Claims Act complaint, whether the seal recently lifted or a Rule 9(b) motion is already due, contact Health Law Alliance's False Claims Act defense attorneys for a free, confidential consultation.
